DOP2003000669A - Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos - Google Patents

Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos

Info

Publication number
DOP2003000669A
DOP2003000669A DO2003000669A DO2003000669A DOP2003000669A DO P2003000669 A DOP2003000669 A DO P2003000669A DO 2003000669 A DO2003000669 A DO 2003000669A DO 2003000669 A DO2003000669 A DO 2003000669A DO P2003000669 A DOP2003000669 A DO P2003000669A
Authority
DO
Dominican Republic
Prior art keywords
vpac2
peptides
hypofisary
cyclass
adelinate
Prior art date
Application number
DO2003000669A
Other languages
English (en)
Spanish (es)
Inventor
Wayne A Froland
Drew N Kelner
Michael L Dumas
Clark Pan
James Whelan
Yu-Chang John Wang
Wei Wang
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DOP2003000669A publication Critical patent/DOP2003000669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
DO2003000669A 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos DOP2003000669A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39573802P 2002-07-12 2002-07-12

Publications (1)

Publication Number Publication Date
DOP2003000669A true DOP2003000669A (es) 2004-01-31

Family

ID=30115918

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000669A DOP2003000669A (es) 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos

Country Status (20)

Country Link
US (2) US7378494B2 (enExample)
EP (1) EP1578358A2 (enExample)
JP (1) JP2006506969A (enExample)
CN (1) CN101405298A (enExample)
AR (1) AR040548A1 (enExample)
AU (1) AU2003267990A1 (enExample)
BR (1) BR0312621A (enExample)
CA (1) CA2491279A1 (enExample)
DO (1) DOP2003000669A (enExample)
GT (1) GT200300142A (enExample)
HN (1) HN2003000217A (enExample)
IL (1) IL165499A (enExample)
MX (1) MXPA04012305A (enExample)
PE (1) PE20040677A1 (enExample)
PL (1) PL377025A1 (enExample)
RU (1) RU2360922C2 (enExample)
TW (1) TW200409641A (enExample)
UY (1) UY27893A1 (enExample)
WO (1) WO2004006839A2 (enExample)
ZA (1) ZA200501118B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
EP1713493A4 (en) * 2004-01-27 2009-06-24 Bayer Pharmaceuticals Corp PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS
US20080096811A1 (en) * 2004-05-21 2008-04-24 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CA2564740A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2005119524A2 (en) 2004-06-04 2005-12-15 Therasense, Inc. Diabetes care host-client architecture and data management system
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
CA2577010A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
WO2006042152A2 (en) 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20060159737A1 (en) * 2004-11-19 2006-07-20 Steffen Panzner Pharmaceutical compositions for local administration
ATE432322T1 (de) * 2004-12-21 2009-06-15 Lubrizol Ltd Zusammensetzungen
WO2006110551A2 (en) * 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
EP1915393A1 (en) * 2005-08-11 2008-04-30 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US7582608B2 (en) * 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
BRPI0708341A2 (pt) * 2006-02-28 2011-05-24 Lilly Co Eli agonistas peptìdicos seletivos do receptor vpac2
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
DK2321640T3 (en) * 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) * 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use

Also Published As

Publication number Publication date
GT200300142A (es) 2004-03-17
HN2003000217A (es) 2004-07-26
MXPA04012305A (es) 2005-02-25
RU2005103396A (ru) 2005-09-20
US20090258826A1 (en) 2009-10-15
IL165499A (en) 2010-12-30
RU2360922C2 (ru) 2009-07-10
UY27893A1 (es) 2003-12-31
CN101405298A (zh) 2009-04-08
EP1578358A2 (en) 2005-09-28
US20040058870A1 (en) 2004-03-25
ZA200501118B (en) 2006-08-30
IL165499A0 (en) 2006-01-15
PE20040677A1 (es) 2004-10-29
TW200409641A (en) 2004-06-16
AR040548A1 (es) 2005-04-13
CA2491279A1 (en) 2004-01-22
US7378494B2 (en) 2008-05-27
JP2006506969A (ja) 2006-03-02
WO2004006839A2 (en) 2004-01-22
AU2003267990A1 (en) 2004-02-02
PL377025A1 (pl) 2006-01-23
BR0312621A (pt) 2005-12-06

Similar Documents

Publication Publication Date Title
DOP2003000669A (es) Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos
DOP2000000071A (es) Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacológico
ES2930750T3 (es) Composición farmacéutica para tratar un síndrome metabólico
JP6229038B2 (ja) 修飾された血管作動性腸管ペプチド
JP6612251B2 (ja) エキセンジン−４に由来するペプチド二重ｇｌｐ−１／グルカゴン受容体アゴニスト
WO2007024899A2 (en) Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US8222217B2 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
PT699686E (pt) Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos
AR061203A1 (es) Moduladores del receptor glp-1 modificados en la terminal n
Nakae et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats
WO2006014287A8 (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20070004619A1 (en) Relaxin superfamily peptide analogues
EA038073B1 (ru) Ацилированное инсулиновое соединение
US8318664B2 (en) Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
ECSP066793A (enExample)
RU2673179C2 (ru) Производное инсулинотропного пептида с модифицированным N-концевым зарядом
ES2635691T3 (es) Uso de relaxina para aumentar la distensibilidad arterial
TW200716156A (en) Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
ECSP003683A (es) Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
WO2024209050A1 (en) Gip activity modulators and orthostatic intolerance
AR025902A1 (es) Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
TH84721A (th) อะโกนิสต์ของตัวรับ (vpac2) ของเปปไตด์ที่กระตุ้นปิตูอิตารี่อะดีนิเลตไซเดลส (pacap) และการใช้วิธีการทางเภสัชวิทยาของมัน
TH87281B (th) N-เทอร์มินัลลี มอดิไฟด์ glp-1 รีเซปเตอร์ มอดูเลเตอร์
Comi Octreotide and Non-GH Pituitary Tumors